Suppr超能文献

降钙素与胰淀素受体肽相互作用机制:深入了解受体活性修饰蛋白对降钙素受体的肽结合模式及变构调节

Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS.

作者信息

Lee Sang-Min, Hay Debbie L, Pioszak Augen A

机构信息

From the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 and.

the School of Biological Sciences and Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1142, New Zealand.

出版信息

J Biol Chem. 2016 Apr 15;291(16):8686-700. doi: 10.1074/jbc.M115.713628. Epub 2016 Feb 19.

Abstract

Receptor activity-modifying proteins (RAMP1-3) determine the selectivity of the class B G protein-coupled calcitonin receptor (CTR) and the CTR-like receptor (CLR) for calcitonin (CT), amylin (Amy), calcitonin gene-related peptide (CGRP), and adrenomedullin (AM) peptides. RAMP1/2 alter CLR selectivity for CGRP/AM in part by RAMP1 Trp-84 or RAMP2 Glu-101 contacting the distinct CGRP/AM C-terminal residues. It is unclear whether RAMPs use a similar mechanism to modulate CTR affinity for CT and Amy, analogs of which are therapeutics for bone disorders and diabetes, respectively. Here, we reproduced the peptide selectivity of intact CTR, AMY1 (CTR·RAMP1), and AMY2 (CTR·RAMP2) receptors using purified CTR extracellular domain (ECD) and tethered RAMP1- and RAMP2-CTR ECD fusion proteins and antagonist peptides. All three proteins bound salmon calcitonin (sCT). Tethering RAMPs to CTR enhanced binding of rAmy, CGRP, and the AMY antagonist AC413. Peptide alanine-scanning mutagenesis and modeling of receptor-bound sCT and AC413 supported a shared non-helical CGRP-like conformation for their TN(T/V)G motif prior to the C terminus. After this motif, the peptides diverged; the sCT C-terminal Pro was crucial for receptor binding, whereas the AC413/rAmy C-terminal Tyr had little or no influence on binding. Accordingly, mutant RAMP1 W84A- and RAMP2 E101A-CTR ECD retained AC413/rAmy binding. ECD binding and cell-based signaling assays with antagonist sCT/AC413/rAmy variants with C-terminal residue swaps indicated that the C-terminal sCT/rAmy residue identity affects affinity more than selectivity. rAmy(8-37) Y37P exhibited enhanced antagonism of AMY1 while retaining selectivity. These results reveal unexpected differences in how RAMPs determine CTR and CLR peptide selectivity and support the hypothesis that RAMPs allosterically modulate CTR peptide affinity.

摘要

受体活性调节蛋白(RAMP1 - 3)决定了B类G蛋白偶联降钙素受体(CTR)和降钙素受体样受体(CLR)对降钙素(CT)、胰淀素(Amy)、降钙素基因相关肽(CGRP)和肾上腺髓质素(AM)肽的选择性。RAMP1/2部分通过RAMP1的色氨酸84或RAMP2的谷氨酸101与CGRP/AM不同的C末端残基接触来改变CLR对CGRP/AM的选择性。尚不清楚RAMP是否使用类似机制来调节CTR对CT和Amy的亲和力,CT和Amy的类似物分别是治疗骨疾病和糖尿病的药物。在这里,我们使用纯化的CTR细胞外结构域(ECD)以及与RAMP1和RAMP2相连的CTR ECD融合蛋白和拮抗剂肽,重现了完整的CTR、AMY1(CTR·RAMP1)和AMY2(CTR·RAMP2)受体的肽选择性。这三种蛋白都能结合鲑鱼降钙素(sCT)。将RAMP与CTR相连可增强rAmy、CGRP和AMY拮抗剂AC413的结合。肽丙氨酸扫描诱变以及受体结合的sCT和AC413的建模支持了它们在C末端之前的TN(T/V)G基序具有共同的非螺旋CGRP样构象。在此基序之后,这些肽出现分歧;sCT的C末端脯氨酸对受体结合至关重要,而AC413/rAmy的C末端酪氨酸对结合几乎没有影响。因此,突变型RAMP1 W84A - 和RAMP2 E101A - CTR ECD保留了AC413/rAmy的结合。使用具有C末端残基交换的拮抗剂sCT/AC413/rAmy变体进行的ECD结合和基于细胞的信号传导分析表明,C末端sCT/rAmy残基的同一性对亲和力的影响大于对选择性的影响。rAmy(8 - 37) Y37P在保留选择性的同时,对AMY1表现出增强的拮抗作用。这些结果揭示了RAMP决定CTR和CLR肽选择性的方式存在意想不到的差异,并支持RAMP变构调节CTR肽亲和力的假设。

相似文献

8
Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product.
Biochem Biophys Res Commun. 2000 Jan 7;267(1):368-72. doi: 10.1006/bbrc.1999.1943.

引用本文的文献

2
Amylin receptor subunit interactions are modulated by agonists and determine signaling.
Sci Signal. 2025 Aug 19;18(900):eadt8127. doi: 10.1126/scisignal.adt8127.
3
Amylin Receptor 1 Mutagenesis Revealed a Potential Role of Calcitonin Serine 29 in Receptor Interaction.
Biomedicines. 2025 Jul 21;13(7):1787. doi: 10.3390/biomedicines13071787.
4
Characterization of the Two-Domain Peptide Binding Mechanism of the Human CGRP Receptor for CGRP and the Ultrahigh Affinity ssCGRP Variant.
Biochemistry. 2025 Apr 15;64(8):1770-1787. doi: 10.1021/acs.biochem.4c00812. Epub 2025 Apr 2.
5
Amylin receptor subunit interactions are modulated by agonists and determine signaling.
bioRxiv. 2024 Oct 9:2024.10.09.617487. doi: 10.1101/2024.10.09.617487.
7
Discovery of potential biomarkers for osteoporosis using LC/GC-MS metabolomic methods.
Front Endocrinol (Lausanne). 2024 Jan 17;14:1332216. doi: 10.3389/fendo.2023.1332216. eCollection 2023.
8
Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries.
Genes (Basel). 2023 Apr 22;14(5):953. doi: 10.3390/genes14050953.
9
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins.
Pharmacol Rev. 2023 Jan;75(1):1-34. doi: 10.1124/pharmrev.120.000180. Epub 2022 Dec 8.
10
Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation.
Front Pharmacol. 2022 Dec 8;13:1040951. doi: 10.3389/fphar.2022.1040951. eCollection 2022.

本文引用的文献

1
Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.
Annu Rev Pharmacol Toxicol. 2016;56:469-87. doi: 10.1146/annurev-pharmtox-010715-103120. Epub 2015 Oct 23.
2
Amylin: Pharmacology, Physiology, and Clinical Potential.
Pharmacol Rev. 2015 Jul;67(3):564-600. doi: 10.1124/pr.115.010629.
3
Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor.
Mol Cell. 2015 Jun 18;58(6):1040-52. doi: 10.1016/j.molcel.2015.04.018. Epub 2015 May 14.
4
Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs.
Eur J Pharmacol. 2015 Sep 15;763(Pt B):196-205. doi: 10.1016/j.ejphar.2015.05.013. Epub 2015 May 14.
5
Engineering high-potency R-spondin adult stem cell growth factors.
Mol Pharmacol. 2015;87(3):410-20. doi: 10.1124/mol.114.095133. Epub 2014 Dec 12.
6
IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
Nature. 2015 Jan 29;517(7536):626-30. doi: 10.1038/nature13910. Epub 2014 Nov 17.
7
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
J Med Chem. 2014 Oct 9;57(19):7838-58. doi: 10.1021/jm500364u. Epub 2014 Jun 24.
8
A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats.
Am J Physiol Endocrinol Metab. 2014 Jul 1;307(1):E24-33. doi: 10.1152/ajpendo.00121.2014. Epub 2014 May 6.
9
Adrenomedullin and cardiovascular diseases.
JRSM Cardiovasc Dis. 2012 Aug 10;1(5):cvd.2012.012003. doi: 10.1258/cvd.2012.012003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验